Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 9/20 | 0.39 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.39 |
| ▸ | MLLT3 | P42568 | 1/20 | 0.38 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.38 |
| ▸ | ACR | P10323 | 1/20 | 0.38 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23041661 | 1.00 | ADORA3 (0.42) | ADORA3ADORA2AADORA2BADORA1GAA | |
| SCHEMBL23041657 | 1.00 | ADORA3 (0.42) | ADORA3ADORA2AADORA2BADORA1GAA | |
| SCHEMBL23042058 | 1.00 | ADORA3 (0.42) | ADORA3ADORA2AADORA2BADORA1GAA | |
| SCHEMBL23042057 | 1.00 | ADORA3 (0.42) | ADORA3ADORA2AADORA2BADORA1GAA | |
| SCHEMBL29452338 | 1.00 | ADORA3 (0.42) | ADORA3ADORA2AADORA2BADORA1GAA | |
| SCHEMBL23041456 | 0.95 | ADORA3 (0.47) | ADORA3ADORA2AADORA2BADORA1GAA | |
| SCHEMBL23041529 | 0.93 | ADORA3 (0.41) | ADORA3ADORA2AADORA2BADORA1GAA | |
| SCHEMBL29452341 | 0.93 | ADORA3 (0.41) | ADORA3ADORA2AADORA2BADORA1GAA | |
| SCHEMBL23041533 | 0.93 | ADORA3 (0.41) | ADORA3ADORA2AADORA2BADORA1GAA | |
| SCHEMBL23041464 | 0.91 | ADORA3 (0.43) | ADORA3ADORA2AADORA2BADORA1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4021572-A1 | SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2022-07-06 | — | — | EP | claimed |
| CN-114341132-A | Substituted 1, 3-phenylheteroaryl derivatives and their use in the treatment of diseases | 诺华股份有限公司 | 2022-04-12 | — | — | CN | claimed |
| US-20220306617-A1 | SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2022-09-29 | — | — | US | disclosed |
| EP-4021572-A1 | SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2022-07-06 | — | — | EP | disclosed |
| CN-114341132-A | Substituted 1, 3-phenylheteroaryl derivatives and their use in the treatment of diseases | 诺华股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306617-A1 | SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | CFTR, TMEM161A, TMEM164 | ADORA3 428/4885ADORA2A 814/4885ADORA2B 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.